@article{7f3c3d23ddec4dd3ac6a19b47be954ab,
title = "Molecular testing in lung cancer: Where to draw the line?",
author = "Balazs Halmos",
note = "Funding Information: Accepted for publication February 22, 2018. Published as an Early Online Release April 6, 2018. From the Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. Dr Halmos receives research funding from Merck, Mirati, Astra-Zeneca, Boehringer-Ingelheim, Pfizer, Takeda, and Eli Lilly. Additionally, he consults with Foundation Medicine, Guardant Health360, Pfizer, Eli Lilly, Genentech, Astra-Zeneca, Novartis, Boehringer-Ingelheim, and Takeda. doi: 10.5858/arpa.2018-0060-ED Corresponding author: Balazs Halmos, MD, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Rd, Bronx, NY 10461 (email: bahalmos@montefiore.org).",
year = "2018",
month = jul,
doi = "10.5858/arpa.2018-0060-ED",
language = "English (US)",
volume = "142",
pages = "787--789",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "7",
}
